Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Verrica Pharmaceuticals Inc. Common Stock

VRCA

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Last trade $2.98
Day change -$0.22 (-6.88%)
Day range $2.78 – $3.66
Volume 77,154
Market cap $55M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$54.97M
Price / earnings
—
Price / book
12.76×
Price / sales
1.81×
EV / sales
1.49×
EV / EBITDA
-1.71×

Profitability

Earnings per share
-$1.82
Return on assets
-86.58%
Return on equity
-724.01%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.32×
Current ratio
1.06×
Quick ratio
0.97×
Cash ratio
0.36×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.35M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VRCA, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$5.86M$5.02M$5.09M$14.34M$12.7M$3.44M$344K-$1.78M
Cost of revenue$878K$889K$1.4M$1.11M$494K$437K$625K$435K
Gross profit$4.98M$4.13M$3.69M$13.24M$12.21M$3M-$281K-$2.22M
Selling, general and administrative$10.35M$9.99M$8.12M$9.4M$8.85M$8.85M$9.88M$16.08M
Research and development$6.03M$3.86M$2.52M$2.21M$1.85M$2.28M$1.17M$2.41M
Total operating expenses$18.08M$13.85M$10.64M$11.61M$10.7M$11.13M$11.05M$18.49M
Operating income-$13.1M-$9.72M-$6.95M$1.63M$1.51M-$8.13M-$11.33M-$20.7M
Interest expense-$164K-$160K-$1.31M-$2.09M-$2.13M-$2.2M-$2.35M-$2.38M
Income before taxes-$13.15M-$9.68M-$8.07M-$274K$204K-$9.74M-$16.2M-$22.86M
Income taxes$0$0$0$0$0$0$0$0
Net income-$13.15M-$9.68M-$8.07M-$274K$204K-$9.74M-$16.2M-$22.86M
Net income attributable to common shareholders-$13.15M-$9.68M-$8.07M-$274K$204K-$9.74M-$16.2M-$22.86M
EBITDA-$11.38M-$9.7M-$6.93M$1.65M$1.55M-$8.08M-$11.27M-$20.64M
Basic earnings per share-$0.62-$0.45-$0.57-$0.03$0.02-$1.03-$2.40-$4.88
Diluted earnings per share-$0.62-$0.45-$0.57-$0.03$0.02-$1.03-$2.40-$4.88

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals announced the first patient dosing in a global Phase 3 clinical trial for YCANTH (VP-102) to treat common warts, a condition affecting approximately 22 million patients in the U.S. with no FDA-approved prescription therapies. The Phase 3 program is based on positive Phase 2 COVE-1 results showing 51% complete clearance of warts. Torii will fund approximately 90% of trial costs on a 50/50 cost-sharing basis, with Verrica's portion covered by future milestones and royalties from Japan.

The Motley Fool

Verrica Posts Profit in Fiscal Q2

Verrica Pharmaceuticals reported strong Q2 2025 financial results, with non-GAAP EPS of $0.25 and GAAP revenue of $12.7 million, significantly exceeding analyst expectations. The company saw improved performance driven by YCANTH product sales and a major milestone payment from Torii Pharmaceutical.

GlobeNewswire Inc.

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Verrica Pharmaceuticals announced the acceptance of two abstracts featuring positive preliminary results from a Phase 2 study of its investigational therapy VP-315 for the treatment of basal cell carcinoma. The data showed promising safety, tolerability, and antitumor efficacy.

GlobeNewswire Inc.

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals reported Q2 2024 financial results, including $4.9M in YCANTH revenue and positive preliminary results from a Phase 2 study of VP-315 for basal cell carcinoma. The company also announced progress in its common warts program and expansion of YCANTH distribution.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 25, 20251-for-10reverse split